Episode 22 — 05 June 2026

NICE approves third DMD treatment givinostat via Innovative Medicines Fund while CHMP's May output signals structural shift toward rare disease therapies. ISPOR 2026 highlights HEOR's expanding role in policy and value frameworks amid accelerating orphan designation trends.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast